ADC vs ZLAB: How Agree Realty Corporation and Zai Lab Limited Compare (2026)

Same yardstick, side by side (as of August 2026). Valuation lined up like this is most meaningful for two names in the same corner of the market, which these are. Figures are approximate; verify before investing.

The metrics above tell you which is the marginally better business. The bigger risk for most people is not picking the slightly worse stock, it is over-concentrating. ADC and ZLAB share themes, so owning both, or adding either to what you already hold, can quietly push a large share of your portfolio into one bet.

This is the part a generic comparison page cannot answer, because it depends on what you own. Connect your brokerage and Walnut shows your real, combined ADC and ZLAB exposure, flags overlap with your existing positions, and tells you if adding one would tip you past a concentration you are comfortable with, read-only by default, with your login staying at your broker. Walnut is not an investment adviser.

Agree Realty Corporation (NYSE: ADC) is a real estate investment trust that acquires and develops freestanding, single-tenant retail properties net-leased to national and regional chains. Under net leases, tenants cover most property costs (taxes, insurance, and maintenance), which gives the REIT predictable rent streams and thin operating overhead. As of the end of 2025 the portfolio held roughly 2,674 properties across all 50 states, totaling about 55.5 million square feet, and was effectively fully leased at 99.7% occupancy. Investment-grade retailers generated close to 67% of annualized base rent, with top tenants including Walmart, Tractor Supply, Dollar General, Best Buy, and TJX, tilting the rent roll toward defensive, needs-based retail.

Full ADC guide

Zai Lab was built on a specific arbitrage: find drugs that already work, license the Greater China rights before or during late-stage development, run the local trials and regulatory process, and sell them through a domestic commercial organization that Western partners do not want to build. That produced a portfolio of marketed products including ZEJULA (niraparib, a PARP inhibitor for ovarian cancer), the VYVGART franchise (efgartigimod, partnered with argenx, for generalized myasthenia gravis), XACDURO (sulbactam-durlobactam for Acinetobacter infections) and NUZYRA (omadacycline), with newer approvals for AUGTYRO, TIVDAK and KarXT rolling into launch through 2026. Total revenue was about $460 million in 2025 and roughly $450 million over the trailing twelve months, and management has described the China commercial business as profitable on its own before corporate R&D.

Full ZLAB guide

Both fit overlapping themes, but they are not interchangeable. The useful comparison is which set of drivers and risks you want exposure to.

• ADC drivers: External growth engine; Investment-grade, defensive tenant base.
• ZLAB drivers: Zoci as the first globally owned asset; Newly approved products entering commercial ramp.

A faster-growing, richer-valued name usually swings harder, so it suits a longer horizon and a higher tolerance for volatility; a steadier, more cash-generative business suits a more conservative or income-minded investor. The honest test is which set of risks you could hold through a drawdown: Interest-rate sensitivity is the dominant risk, since higher rates lift Agree's borrowing costs and make its dividend yield less competitive versus bonds, which can pressure the share price. For ZLAB, zai Lab's revenue is concentrated in mainland China and is therefore exposed to administered pricing rather than market pricing: national reimbursement drug list renewals cut prices as a condition of volume, and volume-based procurement of generics can collapse a branded franchise quickly, which is what happened to ZEJULA when generic olaparib entered.

Growth-minded investors who believe the theme has years to run tend to accept the richer multiple for more upside; value-minded investors lean toward the cheaper forward earnings and steadier profile. Pick ADC if you believe its drivers more; ZLAB if you believe its. Many investors hold both, but since they share themes, that is a concentrated bet, not diversification. Decide deliberately and check overlap. For the full detail, see the ADC and ZLAB guides.

ADC. Agree trades at a premium multiple of AFFO relative to net-lease peers, roughly the high-teens on a price-to-AFFO basis, a level the market has long assigned to its balance-sheet quality and consistency. With 2026 AFFO guided around $4.56 and shares near $80, the valuation prices in reliable but unspectacular growth. Investors are largely paying for durability of income rather than a discount.

ZLAB. There is no earnings multiple to quote because Zai Lab does not earn anything yet, so the stock is valued on revenue, cash and pipeline probability instead. Backing out roughly $717 million of cash leaves about $1.6 billion of enterprise value against $450 million of trailing revenue, which is a low multiple for a specialty pharma commercial base and implies the market assigns close to nothing for the wholly owned oncology pipeline. Bulls point at that gap, bears point at a revenue line that shrank year over year in both Q1 and Q2 2026 while operating expenses stayed above $130 million a quarter.

Headline figures (approximate, FEBRUARY 2026): ADC shows revenue (ttm) ~$715M, affo per share (2025) ~$4.32, affo per share (2026 guidance) ~$4.54 to $4.58, dividend (annualized) ~$3.20 (~4.4% yield); ZLAB shows revenue (ttm) ~$450 million, up ~5% year over year, q2 2026 revenue ~$106.3 million, down ~3% year over year but up ~11% sequentially on product sales, net loss ~$50.8 million in Q2 2026, ~$188 million over the trailing twelve months, cash and investments ~$717.5 million as of June 30, 2026.

ADC and ZLAB are related but distinct: same themes, different businesses and risks. Neither wins in the abstract; the right pick is whichever thesis you actually believe, sized so you are not over-concentrated in one theme. Walnut can show your combined ADC and ZLAB exposure against your real portfolio. It is not an investment adviser.